Joseph Ferguson, MD
Internal Medicine · Fredericksburg, VANPI 1811986441
Payments from drug & device makers
Across 135 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$271
- AbbVie$252
- Esperion Therapeutics, Inc.$191
- Lilly USA, LLC$176
- AstraZeneca$151
- Amgen$149
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,253100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $271 |
| AbbVie(2 entities) | 21 | $252 |
| Esperion Therapeutics, Inc. | 10 | $191 |
| Lilly USA, LLC | 13 | $176 |
| AstraZeneca | 8 | $151 |
| Amgen(2 entities) | 9 | $149 |
| Amarin Pharma, Inc. | 8 | $138 |
| Upsher-smith Laboratories LLC | 5 | $93 |
| Merck | 6 | $90 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Pfizer | 4 | $70 |
| Supernus Pharmaceuticals, Inc. | 3 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Novartis | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Exact Sciences | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| GSK | 1 | $11 |
How this compares
$2,253 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $49,387 |
| EliquisApixaban | 29 | $37,630 |
| JardianceEmpagliflozin | 21 | $25,601 |
| FarxigaDapagliflozin Propanediol | 24 | $22,192 |
| JanuviaSitagliptin Phosphate | 31 | $19,132 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $17,623 |
| MyrbetriqMirabegron | 13 | $8,170 |
| Rosuvastatin Calcium | 439 | $5,252 |
| Saxagliptin Hcl | 23 | $4,637 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,172 |
| Ezetimibe | 145 | $4,162 |
| Levothyroxine Sodium | 208 | $2,137 |
| Fluticasone Propionate | 82 | $2,079 |
| Losartan Potassium | 248 | $1,987 |
| SynthroidLevothyroxine Sodium | 17 | $1,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $271 | $49,38736 claims |
| PfizerEliquis | $70 | $37,63029 claims |
| MerckJanuvia, Janumet | $90 | $36,75544 claims |
| Boehringer IngelheimJardiance | $42 | $25,60121 claims |
| AstraZenecaFarxiga | $151 | $22,19224 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $8,17013 claims |
| AbbVieSynthroid | $252 | $1,95917 claims |
| Upsher-smith Laboratories LLCTopiramate | $93 | $81655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Fredericksburg
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.